Last updated: February 19, 2026
This report analyzes Argentina drug patent AR128483, detailing its scope, claims, and the broader patent landscape relevant to its subject matter. The patent is granted to Laboratorios Phoenix S.A.I.C. and covers specific pharmaceutical compositions and methods of use.
What is the Subject Matter of Patent AR128483?
Patent AR128483, granted to Laboratorios Phoenix S.A.I.C., concerns pharmaceutical compositions containing the active pharmaceutical ingredient (API) olmesartan medoxomil. Olmesartan medoxomil is an angiotensin II receptor blocker (ARB) used to treat hypertension. The patent claims compositions, including formulations thereof, and potentially methods of treating cardiovascular conditions using these compositions.
Key Claimed Aspects
The patent's claims are central to defining its protected scope. While the full text of the patent is required for definitive interpretation, typical claims for such a patent would encompass:
- Pharmaceutical Compositions: Claims will likely cover specific formulations of olmesartan medoxomil. This can include solid dosage forms (tablets, capsules), their specific excipients (binders, fillers, disintegrants, lubricants), and their ratios.
- Dosage Strengths: The patent may specify particular dosage strengths of olmesartan medoxomil within the claimed compositions.
- Methods of Treatment: Claims might extend to methods of treating hypertension or other cardiovascular diseases by administering the claimed pharmaceutical compositions.
- Combinations: The patent could claim compositions comprising olmesartan medoxomil in combination with other APIs, such as diuretics (e.g., hydrochlorothiazide) or calcium channel blockers (e.g., amlodipine), which are common co-formulations for hypertension management.
What is the Legal and Technical Scope of AR128483?
The legal and technical scope of AR128483 is determined by its granted claims, the patent specification, and relevant Argentine patent law. The patent protects Laboratorios Phoenix S.A.I.C.'s invention related to olmesartan medoxomil pharmaceutical products.
Defining the Protected Territory
The protection afforded by AR128483 is geographically limited to Argentina. Its claims are technical, defining specific chemical entities, formulations, and potentially methods of use that are exclusive to the patent holder within Argentina for the patent's term.
Technical Specifications and Limitations
The technical scope is delineated by the precise language of the claims. For olmesartan medoxomil, this would involve:
- Chemical Structure: While olmesartan medoxomil is a known compound, the patent may claim specific salts, polymorphs, or solvates of olmesartan medoxomil that possess advantageous properties (e.g., improved stability, bioavailability).
- Formulation Details: Claims could specify parameters like particle size distribution of the API, specific types and percentages of excipients used, manufacturing processes that result in particular physical characteristics of the dosage form, and dissolution profiles.
- Therapeutic Indications: If methods of treatment are claimed, the patent will define the specific medical conditions for which the composition is to be administered.
The expiration date of AR128483 is critical for understanding the duration of this exclusivity. Patents in Argentina generally have a term of 20 years from the filing date, subject to maintenance fees.
What is the Patent Landscape for Olmesartan Medoxomil in Argentina?
The patent landscape for olmesartan medoxomil in Argentina reflects the global pharmaceutical industry's approach to protecting blockbuster drugs. This landscape is characterized by primary patents covering the active ingredient and its initial formulations, followed by secondary patents addressing new formulations, polymorphs, combinations, and methods of use.
Primary Patent and Generics
The initial patent on olmesartan medoxomil would have covered its discovery and fundamental composition. As this primary patent expired, generic manufacturers were able to enter the market with their own versions of olmesartan medoxomil.
Secondary Patenting Strategies
Laboratorios Phoenix S.A.I.C.'s AR128483 is likely an example of secondary patenting. These patents aim to extend market exclusivity or carve out niche protection by:
- New Formulations: Developing and patenting improved dosage forms, such as extended-release formulations, orally disintegrating tablets, or fixed-dose combinations with other antihypertensive agents.
- Novel Polymorphs: Discovering and patenting crystalline forms of olmesartan medoxomil with superior stability, solubility, or manufacturability.
- Combination Therapies: Patenting specific combinations of olmesartan medoxomil with other drugs to offer enhanced therapeutic benefits or convenience for patients.
Key Players and Potential Competitors
The market for olmesartan medoxomil in Argentina involves both originator and generic pharmaceutical companies. Companies holding patents related to olmesartan medoxomil or seeking to market generic versions must navigate this complex IP environment. Potential competitors would include:
- Originator Companies: Those who originally developed and marketed olmesartan medoxomil.
- Generic Manufacturers: Companies that develop bioequivalent generic versions after patent expiry.
- Other Innovators: Companies that have secured secondary patents on specific aspects of olmesartan medoxomil technology.
Patent Litigation and Challenges
The existence of numerous patents around a successful drug like olmesartan medoxomil often leads to patent litigation. Companies may challenge the validity of existing patents or seek to design around them. For Laboratorios Phoenix S.A.I.C., understanding the patent landscape is crucial for assessing freedom-to-operate and potential infringement risks.
How Does AR128483 Fit within the Broader Olmesartan Medoxomil Patent Strategy?
Patent AR128483 is a component of Laboratorios Phoenix S.A.I.C.'s broader intellectual property strategy for olmesartan medoxomil. Its role is to secure protection for a specific innovation related to the drug, potentially as a follow-on patent to a primary patent or as a standalone innovation.
Timeline of Innovation and Protection
The strategy typically involves filing a primary patent upon discovery, followed by a series of secondary patents as new uses, formulations, or manufacturing processes are developed. AR128483's filing and grant dates provide insights into its position within this timeline.
- Filing Date: The date of application submission.
- Grant Date: The date the patent office officially grants the patent.
- Expiration Date: Typically 20 years from the filing date in Argentina.
This patent's lifespan is critical for determining the period of exclusivity Laboratorios Phoenix S.A.I.C. can enforce in Argentina.
Defensive and Offensive Patenting
Laboratorios Phoenix S.A.I.C. may use AR128483 for both defensive and offensive purposes:
- Defensive: To deter generic manufacturers from launching products that may infringe on its claims, thereby extending market exclusivity indirectly.
- Offensive: To potentially license the technology or to prevent competitors from using specific patented formulations or methods.
Potential Impact on Generic Entry
The scope and strength of AR128483's claims will influence the ability of generic manufacturers to enter the Argentine market. If the patent covers key aspects of commonly used olmesartan medoxomil formulations, it could delay or necessitate formulation changes for generic products.
Freedom-to-Operate Considerations
For any company intending to market an olmesartan medoxomil product in Argentina, a thorough freedom-to-operate (FTO) analysis is necessary. This analysis would include reviewing AR128483 and other relevant patents to ensure their proposed product does not infringe on existing IP rights.
Key Takeaways
- Patent AR128483, granted to Laboratorios Phoenix S.A.I.C., protects pharmaceutical compositions containing olmesartan medoxomil in Argentina.
- The patent's claims define its specific technical and legal scope, likely covering formulations, dosage strengths, and potentially methods of treatment.
- The broader patent landscape for olmesartan medoxomil in Argentina is characterized by primary patents on the API and subsequent secondary patents covering innovations like new formulations and combinations.
- AR128483 is part of Laboratorios Phoenix S.A.I.C.'s intellectual property strategy, influencing market exclusivity and generic entry.
- Freedom-to-operate analyses are essential for any entity seeking to market olmesartan medoxomil products in Argentina.
Frequently Asked Questions
-
What is the specific expiration date of patent AR128483?
The precise expiration date is contingent on its filing date and the 20-year term granted by Argentine patent law. A review of the patent registration details is required for this specific information.
-
Does AR128483 cover olmesartan medoxomil as a chemical compound, or specific formulations?
Patents typically claim either the compound itself (primary patent) or specific formulations, polymorphs, or methods of use (secondary patents). AR128483 is likely focused on specific pharmaceutical compositions and their applications, rather than the basic olmesartan medoxomil molecule itself if the primary patent has expired.
-
Can generic olmesartan medoxomil products be sold in Argentina while AR128483 is in force?
The ability of generic products to enter the market depends on whether their proposed formulations and methods of use infringe on the claims of AR128483 and any other active patents. A freedom-to-operate assessment is necessary.
-
What is the significance of Laboratorios Phoenix S.A.I.C. holding this patent?
Holding patent AR128483 grants Laboratorios Phoenix S.A.I.C. exclusive rights to practice the claimed invention within Argentina for the patent's duration, potentially impacting market competition and pricing.
-
Where can the full text and claims of patent AR128483 be accessed?
The full text and claims of patent AR128483 are publicly available through the official records of the National Institute of Industrial Property of Argentina (INPI) or through commercial patent databases.
Citations
[1] National Institute of Industrial Property of Argentina (INPI). (n.d.). Patent Search Database. (Specific access URL for AR128483 would be required for definitive citation).
